Topics

Emendo Biotherapeutics Company Profile

00:13 EST 23rd January 2020 | BioPortfolio

Emendo Biotherapeutics is transforming the landscape of genome-editing based medicine through its use of novel CRISPR nucleases, advanced cutting-edge protein engineering platforms, diverse pipeline of clinical programs and extensive intellectual property portfolio. For more information please visit us at www.emendobio.com.


News Articles [240 Associated News Articles listed on BioPortfolio]

Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D

Emendo Biotherapeutics, a company aiming to apply CRISPR gene editing to a wider range of genetic diseases, has raised $61 million in financing. The Series B round was led by AnGes, a Japan-based biop...

Emendo Biotherapeutics Achieves Takeda Milestone

Funds will be used to further advance Emendo's nuclease discovery platform and portfolio development programs

Japan's AnGes leads $61M round for biotech startup Emendo

Emendo Biotherapeutics, a startup that says it develops therapies for diseases that are currently untreatable by using the ne -More- 

Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits

CRISPR gene editing offers the potential to selectively edit the genetic mutations causing inherited diseases, but Emendo Biotherapeutics CEO David Baram contends it’s not precise enough. A large nu...

Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program

NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) Read more...

Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics

Expands strategic partnerships with AnGes and Takeda Accelerates novel OMNI gene editing platform into a broad therapeutic product pipeline   Emendo Biotherapeutics, a leader in next-generati...

Gene editing co Emendo Biotherapeutics raises $61m

The company develops next-generation gene editing using synthetic biology to address untreatable diseases.

Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate

The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridg...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Atryn [gtc biotherapeutics, inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Winrho [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use WinRho SDF safely and effectively. See full prescribing information for WinRho SDF. WinRho SDF [Rho(D) Immune Globulin Intravenous (Hu...

Ixinity [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use IXINITY® safely and effectively. See full prescribing information for IXINITY.. IXINITY [coagulation factor IX (recombinant)] Lyophil...

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Biosimilars in developed economies: Overview, status, and regulatory considerations.

Biotherapeutics dominate the pipelines of pharmaceutical companies across the world today with products ranging from hormones, immune-modulators, monoclonal antibodies (mAbs), blood coagulation factor...

Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeutics.

Biotherapeutics may contain a multitude of different post-translational modifications (PTMs) that need to be assessed and possibly monitored and controlled to ensure reproducible product quality. Duri...

TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.

Most immune responses to biotherapeutic proteins involve the development of anti-drug antibodies (ADAs). New drugs must undergo immunogenicity assessments to identify potential risks at early stages i...

Chemoenzymatic synthesis of glycoproteins.

The majority of the world's best-selling biotherapeutics are glycoproteins. However their production using cellular expression systems invariably produces inseparable mixtures of materials which diffe...

Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies.

Immunogenicity against biotherapeutics can lead to the formation of drug/anti-drug-antibody (ADA) immune complexes (ICs) with potential impact on safety and drug pharmacokinetics (PK). This work aimed...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member r...

Companies [114 Associated Companies listed on BioPortfolio]

Emendo Biotherapeutics

Emendo Biotherapeutics is transforming the landscape of genome-editing based medicine through its use of novel CRISPR nucleases, advanced cutting-edge protein engineering platforms, diverse pipeline ...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficu...

EpimAb Biotherapeutics EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunogl...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

More Information about "Emendo Biotherapeutics" on BioPortfolio

We have published hundreds of Emendo Biotherapeutics news stories on BioPortfolio along with dozens of Emendo Biotherapeutics Clinical Trials and PubMed Articles about Emendo Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Emendo Biotherapeutics Companies in our database. You can also find out about relevant Emendo Biotherapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Corporate Database Quicklinks



Searches Linking to this Company Record